logo
Debunking The '54-Year Life Expectancy' Claim For Autistic People

Debunking The '54-Year Life Expectancy' Claim For Autistic People

Forbes2 days ago
Autistic people deserve better than a headline. Yet a widely circulated claim that autistic ... More individuals have an average life expectancy of just 54 years continues to echo across media outlets, high-impact journals, and even federal policy reports.
Autistic people deserve better than a headline. Yet a widely circulated claim that autistic individuals have an average life expectancy of just 54 years continues to echo across media outlets, high-impact journals, and even federal policy reports.
The source? A 2016 study by Hirvikoski et al. has been grossly misinterpreted and misapplied in both academic and public discourse. The reality is far more nuanced, and perpetuating this statistic is not only misleading but also harmful.
According to Andy Shih, Chief Science Officer at Autism Speaks, "Data from credible previous studies suggests a shorter average life expectancy for autistic adults when compared to their peers of about 17 years. However, taking the limitations of those studies into account, we cannot say that this finding is generalizable across the world."
What the Original Study Actually Said About Autistic People
The Hirvikoski study did not find that all autistic people die at 54. In fact, fewer than 3% of the autistic cohort died during the study period, which renders it methodologically incorrect to extrapolate a mean age of death from such a small subset.
"In the 2016 study by Hirvikoski, the authors extrapolated a mean age of death from a small subset," said Kimberly Idoko, MD, Esq., a board-certified neurologist and certified coach. "That's statistically inappropriate, and it creates a distorted picture that doesn't reflect the true life expectancy of autistic people."
Gemma Williams, an academic researcher in the UK, echoed this sentiment. "Only around 3% of the autistic cohort died during the study, but only 0.91% of the non-autistic cohort died. We're still unclear on the percentage of autistic people in the wider population, but what's clear is that autistic people were more likely to have died from almost all types of medical conditions."
Recent studies, such as this 2023 Lancet Regional Health study, provide a more accurate representation of the disparity, showing a life expectancy gap between autistic and non-autistic adults that is significant but not as extreme as the 54-year claim.
The Real Consequences of Autistic Misrepresentation
In a recent open-access study published in JAMA Network Open, researchers Lauren Bishop and Brittany ... More N. Hand analyzed the citations of the Hirvikoski study. Over 70% of citing authors misrepresented their findings.
In a recent open-access study published in JAMA Network Open, researchers Dr. Lauren Bishop and Dr. Brittany N. Hand analyzed the citations of the Hirvikoski study.
Over 70% of citing authors misrepresented their findings. "We expected to find that a sizable minority of articles misrepresented Hirvikoski et al's findings based on our anecdotal experiences as readers, reviewers, and editors," said Dr. Hand. "However, we were surprised to see how widespread these misrepresentations really were."
This misinformation has not been contained within academia. "These misrepresentations have been perpetuated in really high-impact publications and news media," Hand explained. "They even appeared in reports to the U.S. Congress by the Department of Health and Human Services and a continuing education article from the CDC."
The implications are vast. "Misrepresenting mortality statistics for autistic people can cause psychological distress for autistic individuals and their families," Hand added. "Our autistic adult advisory board frequently raises concerns about this narrative." This misinformation can also lead to insurance denials, distorted retirement planning, and worsened stigma.
In her social work course, Dr. Bishop teaches this exact topic and notes that "most of my bachelor's- and master' s-level social work students make the very same interpretation mistakes that the citing authors in our study make." This isn't just about numbers; it's about how we shape perceptions and policies.
Overshadowing Urgent Health Priorities
This misplaced focus on a singular, misleading statistic diverts attention from the actual causes of health disparities. "Perhaps in part because of the misrepresentation of Hirvikoski et al.'s suicide findings," Bishop noted, "autism researchers have increasingly focused on suicide and suicidality instead of studying more prevalent causes of mortality, such as cardiovascular disease."
Ms. Williams points out that in the UK, autistic individuals face significant healthcare barriers, including sensory challenges and communication issues that often prevent them from accessing timely care. "Many autistic people don't get past primary care with problems that quickly escalate," she said. "Add to that background stigma and reduced opportunities to participate in school, work, and social lives, and it paints a bleak picture."
Shih agrees that more inclusive, long-term studies are needed. "Conducting studies like that led by Hirvikoski across every country would give us a more generalizable understanding of autism and aging," he said. "This would point to solutions and opportunities for improvement in these communities."
A More Responsible Narrative For Autistic People
So, how can we improve?
First, by recognizing the responsibilities of researchers, reviewers, and editors. "Authors have a responsibility not to oversensationalize the titles of their research articles to the point of inaccuracy," said Dr. Hand. "Reviewers and editors must check for this."
The term "premature mortality," used in the title of the Hirvikoski paper, is especially problematic. "There is not sufficient evidence from Hirvikoski et al., 2016 to support the idea that, at a population level, autistic people die prematurely," said Hand. Even researchers like Bishop and Hand have begun re-evaluating their own language use. "Now that we know better, we want to do better and start a conversation about it," Hand said.
Dr. Bishop encourages a shift in focus: "Lots of autistic people age well and live long, healthy lives. Health and aging outcomes among autistic people are incredibly heterogeneous. We can do a lot at the individual, family, community, and systems levels to support folks to age and live well."
Partnering with autistic people in the research process is also essential. "We need more information about autistic people's goals and priorities around aging," Hand emphasized. Bishop added that it's time to stop framing aging in autism as solely a problem. "Let's move toward studying healthy aging," she said.
What Comes Next
Shih emphasized that this is a global challenge: "Long-term, longitudinal studies are especially ... More critical to track autistic individuals across their lifespans. These must be fully inclusive, reflecting the full diversity of the autistic community."
Studies of aging in autism are still in their infancy. "Many autism researchers refer to 'aging' autistic populations as those aging into adulthood or middle age," Hand said. "The narrative needs to expand to include aging into and through older adulthood."
Bishop identified several critical, under-discussed issues: "Diagnosis in older adulthood, dementia, cardiovascular disease, reproductive health, and accommodating autistic older adults within the healthcare system all need more attention."
Shih emphasized that this is a global challenge: "Long-term, longitudinal studies are especially critical to track autistic individuals across their lifespans. These must be fully inclusive, reflecting the full diversity of the autistic community."
The myth of the 54-year life expectancy for autistic people has persisted long enough. "It's more important to reckon with reality than let small numbers in one study steer public thinking," said Williams. Responsible communication isn't just good science, it's good humanity.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Many US employers plan to pare health benefits as weight-loss spending soars
Many US employers plan to pare health benefits as weight-loss spending soars

Yahoo

time2 hours ago

  • Yahoo

Many US employers plan to pare health benefits as weight-loss spending soars

By Amina Niasse NEW YORK (Reuters) -More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by consulting firm Mercer on Wednesday. Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers. That is up from 45% of large employers who said they would increase cost-sharing for 2025. Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's Wegovy has surged, with 77% of employers naming them a top issue, the consultancy said. "More clients are saying ... 'I don't know how much longer we can sustain covering these medications'," said Alysha Fluno, a pharmacy innovation leader at Mercer, in an interview. While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some employers facing big cost increases in 2026 may feel this coverage is out of reach," Fluno said. Greater competition in the weight-loss drug market in coming years will give pharmacy benefit managers more negotiating power with drugmakers and drive meaningful cost reductions, said Fluno. Novo's Wegovy and Eli Lilly's Zepbound are listed at $1086 and $1059, respectively, but many patients pay less through their health plans. Prescription drug costs jumped 8% last year, according to the survey. Mercer has forecast a 5.8% rise in overall health benefit costs for 2025. Employers are also eyeing alternatives to traditional pharmacy benefit managers (PBMs), according to Mercer. PBMs such as CVS Caremark, Cigna's Express Scripts and UnitedHealthcare's Optum Rx act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions. Drugmakers say they take an undisclosed cut of the discounts they receive rather than sharing them with patients and payers. Regulatory scrutiny and calls for transparency are fueling interest in new models and emerging PBMs, with 34% of employers considering a switch. The survey found 40% of employers are considering alternative contracting models for their prescription medicine benefits, such as those that price drugs based on the wholesale price that retail pharmacies pay for them. Regulators have criticized the three largest pharmacy benefit managers for steering patients toward more expensive drugs and inflating prices to generate revenue gains, an accusation that the industry denies. California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday that Caremark would replace UnitedHealth's Optum Rx as the fund's PBM in 2026. CalPERS said its five-year contract with Caremark requires the PBM to boost transparency and oversight.

These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs

Yahoo

time2 hours ago

  • Yahoo

These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs

Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Rivals team up: SpaceX sends 24 satellites into orbit for Amazon's Project Kuiper
Rivals team up: SpaceX sends 24 satellites into orbit for Amazon's Project Kuiper

Geek Wire

time2 hours ago

  • Geek Wire

Rivals team up: SpaceX sends 24 satellites into orbit for Amazon's Project Kuiper

A SpaceX Falcon 9 rocket sends Amazon's Project Kuiper satellites into space. (SpaceX / Amazon via LinkedIn) In a case of strange space bedfellows, SpaceX launched 24 satellites for Amazon's Project Kuiper constellation — which is competing with SpaceX's Starlink network to provide internet access from low Earth orbit. A SpaceX Falcon 9 rocket sent the satellites into space from Cape Canaveral Space Force Station in Florida at 2:30 a.m. ET Wednesday (11:30 p.m. PT Tuesday). This was the third launch of operational satellites for Project Kuiper, coming after two batches of 27 satellites each were delivered to orbit in April and June. Those earlier missions made use of United Launch Alliance's Atlas V rockets, but in order to meet its ambitious satellite deployment schedule, Amazon is turning to SpaceX for three Falcon 9 launches. SpaceX enjoys a significant edge over Amazon when it comes to providing satellite broadband access: Starlink has about 8,000 satellites in orbit and more than 6 million subscribers, while Project Kuiper is just getting off the ground. Project Kuiper's satellites are built at an Amazon facility in Kirkland, Wash., not far from the SpaceX complex in Redmond where Starlink satellites are manufactured. Earlier in the evening, a different Falcon 9 rocket lifted off from Vandenberg Space Force Base in California and sent another 26 Starlink satellites into orbit. Both of the Falcon 9 first-stage boosters successfully landed on their respective drone ships in the Pacific and the Atlantic, minutes after launch. About an hour after the Florida liftoff, SpaceX reported that all 24 of the Project Kuiper satellites for the KF-01 mission were successfully deployed — drawing a note of thanks from Panos Panay, Amazon's senior vice president of devices and services. 'Congrats to the amazing Amazon Project Kuiper team on another successful launch, and a big thanks to SpaceX for the ride to space,' Panay said in a LinkedIn post. 'Pumped to have another batch of Kuiper satellites heading into orbit!' Project Kuiper's mission operations center in Redmond took charge of the satellites to check on their health, raise their orbits and prepare for full commissioning. Amazon says it expects to begin delivering service to customers in late 2025. The company's license from the Federal Communications Commission calls for more than 1,600 satellites to be sent into orbit by mid-2026, with the full 3,232-satellite constellation due for deployment by 2029. Unless Amazon and its launch providers pick up the pace dramatically, the company might have to seek an extension.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store